NCT05225285View on ClinicalTrials.gov

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents

PHASE3UnknownINTERVENTIONAL
Enrollment

1,120

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

June 21, 2022

Study Completion Date

March 21, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Inactivated Coronavac/Butantan vaccine

Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart

BIOLOGICAL

BNT162b2 (Pfizer)

BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart

Trial Locations (1)

29041-295

RECRUITING

Valéria Valim, Vitória

Sponsors

Collaborators (1)

Butantan Institute
All Listed Sponsors
collaborator

Centro de Pesquisas René Rachou

OTHER_GOV

collaborator

Butantan Institute

OTHER_GOV

collaborator

Secretaria de Estado da Saúde do Espírito Santo - SESA

UNKNOWN

lead

Federal University of Espirito Santo

OTHER